Viral oncoproteins discriminate between p53 and the p53 homolog p73

Molecular and Cellular Biology

Volumn 18, Issue 11, 1998, Pages 6316-6324

  Marin, Maria Carmen ^a   Jost, Christine A ^a   Irwin, Meredith S ^a   DeCaprio, James A ^a   Caput, Daniel ^b   Kaelin Jr , William G ^a,c,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SANOFI   (France)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; ISOPROTEIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN ANTIBODY; PROTEIN P53; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; DNA VIRUS; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SEQUENCE HOMOLOGY;

EID: 0031741138     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.11.6316     Document Type: Article

References (53)

1. Band, V., S. Dalal, L. Delmolino, and E. J. Androphy. 1993. Enhanced degradation of p53 protein in HPV-E6 and BPV-1 E6 immortalized human mammary epithelial cells. EMBO J. 12:1847-1852.
2. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not oncogenic mutant p53 protein. Genes Dev. 7:2565-2574.
3. Bargonetti, J., I. Reynisdottir. P. N. Friedman, and C. Prives. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev. 6:1886-1898.
4. Braithwaite, A. W., G. E. Blair, C. C. Nelson, J. McGovern, and A. J. Bellett. 1991. Adenovirus E1b-58 kD antigen binds to p53 during infection of rodent cells: evidence for an N-terminal binding site on p53. Oncogene 6:781-787.
5. Caput, D. Unpublished data.
6. Cheng, N. C., N. Van Roy, A. Chan, M. Beitsma, A. Westerveld, F. Speleman, and R. Versteeg. 1995. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p36 region, only one of which is associated with N-myc amplification. Oncogene 10:291-297.
7. Chiba, I., T. Takahashi, M. M. Nau, D. D. D'Amico, D. T. Curiel, T. Mitsudomi, D. L. Buchhagen, D. Carbone, S. Piantadosi, H. Koga, P. T. Reissman, D. J. Slamon, E. C. Holmes, and J. D. Minna. 1990. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603-1610.
8. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-55.
9. Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7:546-554.
10. Diller, L., J. Kassel, C. Nelson, M. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. Baker, B. Vogelstein, and S. Friend. 1990. p53 functions as a cell cycle control protein in osteosarcoma. Mol. Cell. Biol. 10:5772-5781.
11. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
12. Farmer, G., J. Bargonetti, H. Zhu, P. Fridman, R. Prywes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature 358:83-86.
13. Graham, F. L., and A. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. J. Virol. 52:456-467.
14. Harlow, E., L. V. Crawford, D. C. Pim, and N. M. Williamson. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39: 861-869.
15. Harlow, E., and D. Lane. 1988. Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
16. Hollstein, M. K., K. Rice, M. S. Greenblatt, T. Soussi, R. Fucks, T. Sorlie, E. Hovig, B. Smith-Sorenson, R. Montesano, and C. C. Harris. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:3551-3555.
17. Hoppe-Seyler, F., and K. Butz. 1993. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J. Virol. 67:3111-3117.
18. Hsieh, J., S. Fredersdorf, T. Kouzarides, K. Martin, and X. Lu. 1997. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11:1840-1852.
19. Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO 10:4129-4135.
20. Jiang, D., A. Srinivasan, G. Lozano, and P. D. Robbins. 1993. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 8:2805-2812.
21. Jost, C., M. Marin, and W. G. Kaelin. 1997. p73 is a human p53-related protein that can induce apoptosis. Nature 389:191-194.
22. Jost, C. A., D. Ginsberg, and W. G. Kaelin. 1996. A conserved region of unknown function participates in the recognition of E2F family members by the adenovirus E4 ORF 6/7 protein. Virology 220:78-90.
23. Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J.-C. Biscan, A. Valent, A. Minty, P. Chalon, J.-M. Lelias, X. Dumont, P. Ferrara, F. McKeon, and D. Caput. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
24. Kao, C. C., P. R. Yew, and A. J. Berk. 1990. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179:806-814.
25. Kierstead, T. D., and M. J. Tevethia. 1993. Association of p53 binding and immortalization of primary C57BL/6 mouse embryo fibroblasts by using simian virus 40 T-antigen mutants bearing internal overlapping deletion mutations. J. Virol. 67:1817-1829.
26. Kowalik, T., J. DeGregori, J. Schwarz, and J. Nevins. 1995. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol. 69:2491-2500.
27. Lane, D. P., and L. V. Crawford. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261-263.
28. Li, B., and S. Fields. 1993. Identification of mutations in p53 that affect its binding to SV40 large T antigen by using the yeast two-hybrid system. FASEB J. 7:957-963.
29. Li, X., and P. Coffino. 1996. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70:4509-4516.
30. Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several hydrophobic amino-acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1235-1246.
31. Linzer, D. I. H., and A. J. Levine. 1979. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52.
32. Mansur, C. P., B. Marcus, S. Dalal, and E. J. Androphy. 1995. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 10:457-465.
33. Mietz, J. A., T. Unger, J. M. Huibregtse, and P. M. Howley. 1992. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO 11:5013-5020.
34. Osada, M., M. Ohba, C. Kawahara, C. Ishioka, R. Kanamaru, I. Katoh, Y. Ikawa, Y. Nimura, A. Nakagawara, M. Obinata, and S. Ikawa. 1998. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat. Med. 4:839-843.
35. Pavletich, N. P., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 7:2556-2564.
36. Phillips, A., S. Bates, K. Ryan, K. Helin, and K. Vousden. 1997. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 11:1853-1863.
37. Polyak, K., Y. Xia, J. Zweier, K. Kinzler, and B. Vogelstein. 1997. A model for p53-induced apoptosis. Nature 389:300-305.
38. Qin, X. Q., D. M. Livingston, W. G. Kaelin, and P. Adams. 1994. Deregulated E2F1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 91:10918-10922.
39. Ruppert, J., and B. Stillman. 1993. Analysis of a protein-binding domain of p53. Mol. Cell. Biol. 13:3811-3820.
40. Scheffner, M., T. Takahashi, J. Huibregtse, J. Minna, and P. Howley. 1992. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J. Virol. 66:5100-5105.
41. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomaviruses types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
42. Schmale, H., and C. Bamberger. 1997. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15:1363-1367.
43. Segawa, K., A. Minowa, K. Sugaswa, T. Takano, and F. Hanaoka. 1993. Abrogation of p53-mediated transactivation by SV40 large T antigen. Oncogene 8:543-548.
44. Shan, B., and W.-H. Lee. 1994. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 14:8166-8173.
45. Sturzbecher, H. W., T. Maimets, P. Chumakov, R. Brain, C. Addison, V. Simanis, K. Rudge, R. Philp, M. Grimaldi, W. Court, and J. R. Jenkins. 1990. p53 interacts with p34 cdc2 in mammalian cells: implication for cell cycle control and oncogenesis. Oncogene 5:795-801.
46. Takeda, O., C. Homma, N. Maseki, M. Sakurai, N. Kanda, M. Schwab, Y. Nakamura, and Y. Kaneko. 1994. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chrom. Cancer 10:30-39.
47. Trink, B., K. Okami, L. Wu, V. Sriuranpong, J. Jen, and D. Sidransky. 1998. A new human p53 homologue. Nat. Med. 4:747.
48. Versteeg, R., H. Caron, N. C. Cheng, P. van der Drift, R. Slater, A. Westerveld, P. A. Voute, O. Delattre, G. Laureys, N. Van Roy, and F. Speleman. 1995. 1p36: every subband a suppressor. Eur. J. Cancer 31A:538-541.
49. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2586.
50. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
51. Wu, X., and A. J. Levine. 1994. p53 and E2F1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91:3602-3606.
52. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early E1B protein. Nature 357:82-85.
53. Zalvide, J., and J. A. DeCaprio. 1995. Role of pRB-related proteins in simian virus 40 large T-antigen-mediated transformation. Mol. Cell. Biol. 15:5800-5810.